Renibus Therapeutics, Inc.
Last verified 2026-06-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $110.9Mattributed |
|---|---|
| Latest round | Funding round, $110.9M, 2025-07-17attributed |
| Founded | unknown |
| Headquarters | Southlake, Texas |
| Industry | pharmaceuticals |
| Stage | unknown |
| Website | renibus.com |
Renibus Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cardiac, renal, and metabolic diseases. Its lead drug veverimer targets metabolic acidosis in chronic kidney disease patients heading into Phase 3 trials. The therapy is an oral non-absorbed polymer that raises serum bicarbonate without adding sodium, avoiding a complication common to existing options.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-17 | Funding round | $110.9M | undisclosed |
Detected tech stack
cloudflare, cloudflare bot management, doubleclick floodlight, google analytics, google tag manager, http/3, mysql, php, shopify, site kit 1.180.0, slider revolution, trident ab
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $110.9M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $110.9M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | renibus.com, read 2026-06-14 |
| Description | self-reported | renibus.com, read 2026-06-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $110.9M, 2025-07-17 → Funding round, $110.9M, 2025-07-17, sec-edgar, No document URL on file | Latest round | seed, $110.9M, 2025-07-17 → Funding round, $110.9M, 2025-07-17 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes